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The calcium-sensing receptor (CaSR) is a family C G-protein–coupled receptor that plays a pivotal
role in extracellular calcium homeostasis. The CaSR is also highly expressed in pancreatic islet a- and
b-cells that secrete glucagon and insulin, respectively. To determine whether the CaSR may in-
fluence systemic glucose homeostasis, we characterized a mouse model with a germline gain-of-
function CaSR mutation, Leu723Gln, referred to as Nuclear flecks (Nuf). Heterozygous- (CasrNuf/+)
and homozygous-affected (CasrNuf/Nuf) mice were shown to have hypocalcemia in association with
impaired glucose tolerance and insulin secretion. Oral administration of a CaSR antagonist com-
pound, known as a calcilytic, rectified the glucose intolerance and hypoinsulinemia of CasrNuf/+mice
and ameliorated glucose intolerance in CasrNuf/Nuf mice. Ex vivo studies showed CasrNuf/+ and
CasrNuf/Nuf mice to have reduced pancreatic islet mass and b-cell proliferation. Electrophysiological
analysis of isolated CasrNuf/Nuf islets showed CaSR activation to increase the basal electrical activity of
b-cells independently of effects on the activity of the adenosine triphosphate (ATP)–sensitive
K+ (KATP) channel. Casr
Nuf/Nuf mice also had impaired glucose-mediated suppression of glucagon
secretion, whichwas associatedwith increased numbers of a-cells and a higher a-cell proliferation
rate. Moreover, CasrNuf/Nuf islet electrophysiology demonstrated an impairment of a-cell mem-
brane depolarization in association with attenuated a-cell basal KATP channel activity. These
studies indicate that the CaSR activation impairs glucose tolerance by a combination of a- and b-cell
defects and also influences pancreatic islet mass. Moreover, our findings highlight a potential ap-
plication of targeted CaSR compounds formodulating glucosemetabolism. (Endocrinology 158:
2486–2502, 2017)
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Glucose homeostasis is tightly regulated by the jointactions of insulin and glucagon, which are secreted
from the pancreatic islet b- and a-cells, respectively (1, 2).
Diabetes mellitus is a bihormonal disorder that af-
fects.330million people worldwide and is characterized
by reduced insulin secretion and aberrant glucagon se-
cretion, which arises from alterations in islet function
as well as mass (1, 2). G-protein–coupled receptors
(GPCRs), which comprise the largest superfamily within
the human proteome and are targeted by 40% of all
currently approved drugs (3), facilitate the effects of di-
verse extracellular stimuli, ranging from fatty acids to
neurotransmitters and gut hormones, on a- and b-cells
and represent an exploitable target for the modulation of
glucose homeostasis (4, 5). The extracellular calcium
(Ca2+o)-sensing receptor (CaSR) is a family C GPCR that
plays a key role in the parathyroid and renal regulation of
Ca2+o homeostasis by coupling to intracellular signal
transduction cascades that include the Gq/11-mediated
stimulation of phospholipase C, which increases inositol
1,4,5-trisphosphate, thereby leading to a rapid rise in
cytosolic calcium (Ca2+i) concentrations, and activating
the mitogen-activated protein kinase pathway (6). The
CaSR is also highly expressed in pancreatic islet a- and
b-cells (7, 8), and studies involving isolated human islets
and insulin-secreting cell lines have shown that activation
of the CaSR following exposure to elevated Ca2+o con-
centrations or allosteric activators triggers transient
stimulations of insulin and glucagon secretion, which
were associated with upregulation of phospholipase C
andmitogen-activated protein kinase–mediated signaling
responses (8–10). Moreover, a study involving wild-type
(WT) mice has demonstrated pancreatic islet CaSR ex-
pression to be associated with insulin secretion in vivo
(11). However, the role of this GPCR in systemic glucose
homeostasis is unclear. For example, one patient-based
association study has reported a common coding region
CaSR gene variant to be an independent determinant
of plasma glucose concentrations (12), whereas an-
other study of patients with familial hypocalciuric
hypercalcemia (FHH), which is caused by germline loss-
of-function CaSR mutations, did not reveal any alter-
ations in glucose tolerance or insulin secretion (13).
However, it may be that gain-of-function CaSR muta-
tions, which cause autosomal dominant hypocalcemia
(ADH) (14), are associated with abnormalities of glucose
homeostasis and not FHH-associated loss-of-function
CaSR mutations. To investigate this possibility, we
have evaluated glucose tolerance and pancreatic islet
function in a mouse model for ADH due to a germline
gain-of-function CaSR mutation, Leu723Gln, referred to
as Nuclear flecks (Nuf) because the mouse was initially
identified to have cataracts (15, 16). Our analysis of these
Nufmice has demonstrated a role for the CaSR in glucose
homeostasis.
Materials and Methods
Animals
All study animals were littermates aged between 20 and
28 weeks and kept in accordance with Home Office welfare
guidance in an environment controlled for light (12 hours light
and dark cycle), temperature (21°C 6 2°C), and humidity
(55% 6 10%) at the Medical Research Council Harwell
Centre. Mice had free access to water (25 ppm chlorine) and
were fed ad libitum on a commercial diet (RM3; Special Diet
Services, Essex, United Kingdom) that contained 1.24% cal-
cium, 0.83% phosphorus, and 2948 IU/kg vitamin D. Nuf
mice were maintained on the inbred 102/H background, which
is a substrain bred at the Mary Lyon Centre (Harwell, United
Kingdom) (15, 16). Animal studies were carried out in accor-
dance with GlaxoSmithKline policy on the care, welfare, and
treatment of animals, approved by the Medical Research
Council Harwell Institute Ethical Review Committee, and li-
censed under the Animal (Scientific Procedures) Act 1986,
issued by the UK Government Home Office Department
(PPL30/2752).
Compounds
Ronacaleret, which is also known as SB-751689, was pro-
vided by GlaxoSmithKline (London, United Kingdom) and
dissolved in a 20% aqueous solution of 2-hydroxypropyl-
b-cyclodextrin (catalog no. H107; Sigma-Aldrich, St. Louis,
MO) prior to use in in vitro and in vivo studies.
Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were cultured in
high-glucose Dulbecco’s modified Eagle medium (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum, as
described (17). WT (Leu723) and mutant (Gln723) CaSR-
pEGFP-N1 constructs were generated, as reported (16), and
transiently transfected into HEK293 cells using Lipofectamine
Plus (Invitrogen), as described (16). Successful transfection of
WT and mutant CaSR proteins was confirmed by visualizing
green fluorescent protein (GFP) fluorescence using an
Eclipse E400 fluorescence microscope with an epifluorescence
filter, and images were captured using a DXM1200C digital
camera and NIS Elements software (Nikon, Tokyo, Japan), as
described (17).
Measurement of Ca2+i responses
The effect of ronacaleret on the Ca2+i responses of CaSR-
expressing cells was assessed by a flow cytometry-based assay,
as reported (17, 18). In brief, 48 hours after transfection, the
cells were harvested, washed in calcium- and magnesium-free
Hank’s balanced salt solution (Invitrogen), and loaded with
1 mg/mL indo-1-acetoxymethylester (Molecular Probes,
Eugene, OR) for 1 hour at 37°C (17, 18). After the removal
of free dye, the cells were resuspended in calcium- and
magnesium-free Hank’s balanced salt solution and maintained
at 37°C. Transfected cells were incubated with either a 20%
aqueous solution of 2-hydoxypropyl-b-cyclodextrin (vehicle) or
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ronacaleret at concentrations of 20 and 40 nM for 1 hour, as
described (18). Flow cytometrywas performed using a Beckman
Coulter MoFlo XDP equipped with a JDSUY Xcyte ultraviolet
laser and a Coherent Sapphire 488 laser with a 550LP dichroic
mirror and 580/30 bandpass filter (17). Single cells were isolated
and stimulated by sequentially adding calcium to increase the
Ca2+o concentration ([Ca
2+]o) in a stepwise manner from 0 to
15 mM. The baseline fluorescence ratio was measured for
2 minutes, the fluorescence ratio compared with the time was
recorded, and data were collected for 2 minutes at each [Ca2+]o, as
described (17, 18). Cytomation Summit software was used to de-
termine the peak mean fluorescence ratio of the transient response
after each individual stimulus, whichwas expressed as a percentage
of normalized response (17, 18). Nonlinear regression of the
concentration-response curves was performed with GraphPad
Prism to calculate the half-maximal effective concentration
(EC50) responses for each separate experiment (17).
Effect of ronacaleret on the glucose tolerance of
Nuf mice
Ronacaleret (20 mg/mL) or drug vehicle was administered by
twice daily oral gavage to mice over a 5-day period. The mice
were then tested using the international mouse phenotyping
consortiumglucose tolerance test protocol (www.mousephenotype.
org/impress/protocol/87/7). Briefly, mice were fasted for 16 hours,
and a blood sample was obtained before intraperitoneal (IP)
administration of a 2-g/kg glucose load. Subsequent blood
sampleswere taken at 30, 60, and120minutes for plasmaglucose
and glucagon measurements or at 10, 20, and 30 minutes for
plasma insulin measurements, as described (19).
Body composition analysis
Fat and lean body mass of nonanesthetized live mice were
measured using the Echo-MRI Analyzer system (Echo Medical
Systems, Houston, TX), as described (20).
Islet insulin and glucagon secretion
Pancreatic islets were isolated from whole mouse pancreata
by collagenase digestion and separated from the suspension, as
described (19). Islets were used for secretion experiments within
2 hours of isolation. Batches of 13 size-matched islets were
incubated for 1 hour at 37°C in 0.3 mL of modified Krebs-
Ringer buffer containing 2 mg/mL bovine serum albumin,
1.6 mM CaCl2, and 3 mM glucose, followed by a 1-hour
incubation in 0.3 mL of the same Krebs-Ringer buffer sup-
plemented with 1, 6, or 20 mM glucose, as described (21). A
Krebs-Ringer buffer containing 0.8 mM CaCl2 was used to
evaluate the effect of lowering the [Ca2+]o on islet hormone
secretion. The supernatant was used for measurement of se-
creted insulin and glucagon, and islets were lysed in cold acid
ethanol for measurement of insulin and glucagon content. In-
sulin and glucagon were determined by radioimmunoassay
(Millipore UKLtd, Livingstone, UnitedKingdom) or using a rat/
mouse insulin and glucagon duplex enzyme-linked immuno-
sorbent assay (ELISA; Meso Scale Discovery, Rockville, MD).
Quantitative reverse transcription polymerase
chain reaction
Total RNA from isolated islets was extracted using an
RNeasy Mini Kit (Qiagen, Hilden, Germany), and comple-
mentary DNA was generated by the Superscript II enzyme
(Invitrogen), as described (19). QuantiTect primer assays were
used to amplify selected genes (Arx, Ccnd2, Foxm1, Foxo1,
Irx2, Nkx6, Pax4, Pax6, Pdx1, and Tcf7l2), which were
analyzed by quantitative reverse transcription polymerase
chain reaction (qRT-PCR) using SYBR Green (Qiagen) on the
StepOnePlus qRT-PCRsystem (LifeTechnologies, Carlsbad,CA),
as described (22). The DDCt method was used to calculate fold
change alterations in gene expression, relative to a housekeeping
panel comprising the Actb, Eef1b2, and Gapdh genes (22).
Biochemical analysis
Blood samples were collected from the lateral tail vein of
study mice following application of topical local anesthesia, as
reported (23), or collected from the retro-orbital vein under
isoflurane terminal anesthesia. Plasma was separated by cen-
trifugation at 5000g for 10 minutes at 8°C and analyzed for
calcium and albumin on a BeckmanCoulter AU680 analyzer, as
described (15). Plasma calcium was adjusted for variations in
albumin concentrations using the formula: plasma calcium
(mmol/L) – ([plasma albumin (g/L) – 30] 3 0.02), as reported
(23). Plasma glucose concentrations were measured using an
Analox GM9 analyzer, as described (19). Plasma insulin con-
centrations were measured using a rat/mouse insulin ELISA
(Millipore, Billerica, MA), as described (19), and plasma glu-
cagon concentrations were measured using a rat/mouse glu-
cagon ELISA (Mercodia, Uppsala, Sweden).
Islet electrophysiology
Electrical activity was measured from a- and b-cells within
intact mouse islets using the perforated-patch technique, as
described (24), and all measurements were obtained at 34°C.
Islets were immobilized using a wide-bore glass suction pipette
(24) and perfused with modified Krebs-Ringer solution
(140 mMNaCl, 3.6 mMKCl, 1.5 mMCaCl2, 0.5 mMMgSO4,
10 mM HEPES, 0.5 mM NaH2PO4, and NaHCO3 at pH 7.4
with NaOH and glucose as indicated), as reported (25). A
Krebs-Ringer solution containing 0.75 mM CaCl2 was used to
evaluate the effect of lowering the [Ca2+]o on islet electrical
activity. The solution within the pipet contained 76mMK2SO4,
10 mM KCl, 10 mM NaCl, 1 mM MgCl2, and 5 mM HEPES
(pH 7.35 using KOH) (24). To perforate the cell membrane,
amphotericin B (6 mg/mL) was added to the intracellular buffer.
The conductance of the b-cell adenosine triphosphate (ATP)–
sensitive K+ (KATP) channel within intact islets was measured
using the perforated patch-clamping technique following ex-
posure to different glucose concentrations or to tolbutamide
(24). During the KATP channel conductance studies, b-cells were
held at –70 mV, and K+ currents were evoked by exposing the
cells to alternating 50 ms pulses of –60 or –80 mV (25). Islet cell
types were established by their electrical activity in response to
glucose, and cells that were electrically active at 1 mM glucose
were identified as a-cells (26). Furthermore, b-cells were dis-
tinguished from non-b-cells by the absence of a voltage-gated
Na+ current when a transient pulse from –70 to 0 mV was
applied (21).Measurements were undertaken in individual islets
using an EPC-10 patch-clamp amplifier (HEKA Electronics,
Ludwigshafen/Rhein, Germany) and Pulse software (version
8.50), as described previously (24).
Islet area analysis
Mouse pancreata were fixed in 10% neutral buffered for-
malin, mounted longitudinally, and paraffin embedded, as
2488 Babinsky et al CaSR Activation in Mice Causes Hyperglycemia Endocrinology, August 2017, 158(8):2486–2502
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/article-abstract/158/8/2486/3860207 by U
niversity of U
lster user on 05 February 2020
described (19). Serial sections (4.5mm)were cut, and every 10th
section stainedwith hematoxylin and eosin (H&E), as described
(19). Images of $10 H&E-stained sections per mouse were
acquired at a 320 magnification using the semiautomated
TissueFax slide-scanning microscope (TissueGnostics, Vienna,
Austria), as described (27). Islets were identified, and islet area,
size, and number were quantified using HistoQuest software
(TissueGnostics) (27). Islet area was normalized to the total
section area and to body weight, and islet size was calculated by
dividing the total islet area per section by the number of islets on
the same section.
Islet immunohistochemistry
Immunohistochemistry was undertaken using paraffin-
embedded pancreatic sections that had been subjected to
heat-induced epitope retrieval in citrate buffer (pH 6.0), fol-
lowed by blocking in 10% donkey serum for 1 hour. Primary
antibodies used for insulin, glucagon, and Ki-67 staining were
guinea pig anti-insulin (1:200; ab7842, Abcam [research re-
source identifier (RRID): AB_306130]), rabbit anti-glucagon
[1:200; ab92517, Abcam (RRID: AB_10561971)], and rabbit
anti-Ki67 [1:500; ab15580, Abcam (RRID: AB_443209)], re-
spectively. Secondary antibodies used were donkey anti–guinea
pig [706-225-148, Cy2, Jackson (RRID: AB_2340467)] 1:100
and donkey anti-rabbit [711-165-152, Cy3, Jackson (RRID:
AB_2307443)] 1:500 in phosphate-buffered saline. Sections
were mounted in ProLong Gold Antifade Reagent containing
40,6-diamidino-2-phenylindole (DAPI; Life Technologies). Im-
ages of whole sections were acquired using the TissueFax slide-
scanning microscope (TissueGnostics), as described (27).
Quantification of immunofluorescence signals was undertaken
using the semiautomated intensity detection function of the
TissueQuest software (TissueGnostics), as described (27). The
numbers of a- and b-cells within individual islets were quan-
tified using the cell-based analysis profile of the TissueQuest
software (27), normalized to the total islet area, and reported as
percentage of the mean numbers of Casr+/+ a- and b-cells,
respectively.
Statistical analysis
The in vitro studies involved two separate transfection ex-
periments and eight to nine technical assays. Statistical com-
parisons of the EC50 responses were undertaken using the F test
(17, 18). For the in vivo and ex vivo studies, theMann-Whitney
U test was used to compare differences between two groups, and
the Kruskal-Wallis test was used to compare multiple groups.
An unpaired Student t test was used to compare groups with
small sample sizes (n , 5), as reported (28). All analyses were
undertaken using GraphPad Prism (GraphPad), and a value of
P , 0.05 was considered significant for all analyses.
Results
Nuf mice have impaired glucose tolerance that is
ameliorated by a CaSR allosteric modulator
To establish whether the gain-of-function CaSR muta-
tion in Nuf mice may be associated with alterations in
glucose homeostasis, IP glucose tolerance testing (IPGTT)
was performed onWT (Casr+/+), heterozygous- (CasrNuf/+),
and homozygous-affected (CasrNuf/Nuf) mice aged 20 to
28 weeks that had been fasted for 16 hours. Plasma
glucose concentrations were measured at 0, 30, 60, and
120 minutes following an IP 2-g/kg glucose bolus in-
jection. Male and female CasrNuf/+ and CasrCasrNuf/Nuf
mice had elevated plasma glucose concentrations at 30
and 60 minutes, which were significantly (P , 0.01)
greater than those of respective Casr+/+ mice [Fig. 1(a)
and 1(b)]. The impaired glucose tolerance was not as-
sociated with any alterations in body weight or in fat or
lean mass (Supplemental Fig. 1). To test whether the
impaired glucose tolerance ofNufmicemay be associated
with abnormalities of insulin secretion in vivo, an IPGTT
was conducted with plasma samples collected for insulin
measurement at 0, 10, 20, and 30minutes. Plasma insulin
concentrations of male and femaleCasr+/+mice increased
twofold at 10 minutes after an IP 2 g/kg glucose bolus
injection [Fig. 1(c) and 1(d)]. However, male affected
CasrNuf/+ and CasrNuf/Nuf mice showed significantly re-
duced plasma insulin concentrations at 10 and 20 min-
utes following glucose administration [Fig. 1(c)], whereas
only female CasrNuf/Nuf mice showed significantly re-
duced insulin concentrations at 20 minutes [Fig. 1(d)]
compared with respective Casr+/+ mice. Affected male
CasrNuf/Nuf mice were also shown to have an inadequate
suppression of plasma glucagon concentrations at the 30-
minute time point during a 120-minute IPGTT [Fig. 1(e)],
whereas female CasrNuf/Nuf mice had significantly raised
plasma glucagon concentrations at 120 minutes [Fig.
1(f)]. No significant differences in the glucose, insulin,
or glucagon responses were noted between male and
female mice (Supplemental Fig. 2).
To investigate if the impaired glucose tolerance ofNuf
mice, which have the Leu723Gln gain-of-function CaSR
mutation, could be corrected by a selective CaSR negative
allosteric modulator (i.e., calcilytic agent), we assessed
the in vitro and in vivo effects of ronacaleret, a calcilytic
compound (29). For the in vitro studies, HEK293 cells
were transiently transfected withWT (Leu723) or mutant
(Gln723) CASR-pEGFP-N1 constructs, which express
the CaSR protein fused to the N terminus of enhanced
GFP (16), and the effect of ronacaleret on the responses of
Ca2+i concentrations to alterations in [Ca
2+]o was
assessed. HEK293 cells expressing the mutant Gln723
CaSR [Fig. 2(a)] were shown to have a leftward shift of
the concentration-response curve [Fig. 2(b)], with a sig-
nificant reduction in EC50 (2.63 6 0.08 mM) compared
with WT (2.92 6 0.06 mM; P , 0.01) [Fig. 2(c)], con-
sistent with a gain-of-function, as reported (16). A dose
titration of ronacaleret revealed 20 and 40 nM concen-
trations of this calcilytic compound to normalize the EC50
values and shift in the concentration-response curve of
mutant Gln723-expressing cells [Fig. 2(b) and 2(c)].
Glucose has recently been reported to lead to allosteric
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activation of the CaSR (30), andwe investigated the effect
of alterations in glucose concentrations on the Ca2+i
responses of WT and Nuf mutant Gln723 CaSRs, which
were stably expressed in HEK293 cells (Supplemental
Fig. 3). Our findings showed that altering the glucose
concentration from 3 to 25mMhad no effect on the EC50
values of cells stably expressing WT or Nuf mutant
Gln723 CaSRs, whereas the addition of 40 nM rona-
caleret significantly increased the EC50 values of these
cells (Supplemental Fig. 3). To determine whether ame-
lioration of CaSR gain-of-function by ronacaleret may
lead to an improvement in glucose tolerance in vivo, we
Figure 1. Plasma glucose, insulin, and glucagon concentrations during IPGTT testing. (a) Male and (b) female CasrNuf/+ (blue) and CasrNuf/Nuf mice
(red) are significantly hyperglycemic compared with respective Casr+/+ mice (black) during a 2-hour IPGTT. (c) Male and (d) female CasrNuf/Nuf mice
and male CasrNuf/+ mice have significantly reduced plasma insulin concentrations compared with respective Casr+/+ mice during a 30-minute
IPGTT. (e) Male and (f) female CasrNuf/Nuf mice show significant elevations in plasma glucagon concentrations compared with respective
Casr+/+ mice during a 2-hour IPGTT. Results are expressed as mean 6 standard error of the mean. *P , 0.05, **P , 0.01, and ***P , 0.001
compared with Casr+/+ mice at respective time points.
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administered this calcilytic agent to Nuf mice. Male and
female Casr+/+, CasrNuf/+, and CasrNuf/Nuf mice were
given ronacaleret or drug vehicle for 5 days by twice-daily
oral gavage. Ronacaleret was administered at a dose of
90 mg/kg, as pilot studies had shown this dose to increase
plasma calcium concentrations and to be well tolerated in
Casr+/+ mice. Untreated CasrNuf/+ and CasrNuf/Nuf mice
were shown to be significantly hypocalcemic compared
with Casr+/+ mice, and CasrNuf/Nuf mice had significantly
lower plasma calcium concentrations thanCasrNuf/+mice
[Fig. 2(d) and 2(e)]. Ronacaleret treatment significantly
(P , 0.01) increased plasma calcium concentrations in
male and female Casr+/+, CasrNuf/+, and CasrNuf/Nuf mice
compared with respective untreated mice [Fig. 2(d) and
2(e)]. Ronacaleret treatment normalized the plasma
calcium concentrations ofmale and femaleCasrNuf/+mice
[Fig. 2(d) and 2(e)]. However, the plasma calcium con-
centrations of treated CasrNuf/Nuf mice remained signif-
icantly reduced compared with untreated Casr+/+ mice
[Fig. 2(d) and 2(e)]. Ronacaleret treatment had no effect
on the plasma glucose concentrations of male and female
Casr+/+ mice (Figs. 3 and 4) but significantly (P , 0.05)
improved glucose tolerance in male and female CasrNuf/+
and CasrNuf/Nuf mice compared with respective mice
Figure 2. Effect of ronacaleret on the CaSR gain-of-function and hypocalcemia of Nuf mice. (a) Fluorescence microscopy of HEK293 cells
transiently transfected with WT Leu723 or mutant (m) Gln723 CASR-pEGFP-N1 constructs. GFP expression in these cells indicates successful
transfection and expression by these constructs. Bar indicates 10 mm. (b) Effect of ronacaleret treatment on the intracellular calcium responses of
the Gln723 CaSR mutant. The Gln723 CaSR mutant led to a leftward shift in the concentration-response curve (solid red line) compared with the
WT (Leu723) CaSR (solid black line). The addition of ronacaleret (Rona) at 20- and 40-nM concentrations rectified the leftward shift of the
Gln723 CaSR mutant (blue dashed line and green dashed line, respectively). The zoomed-in image shows the concentration-response curves at
the EC50 values of the WT and mutant CaSRs. (c) Effect of 20 and 40 nM ronacaleret on the EC50 values of the Gln723 CaSR mutant. (d) Male
and (e) female CasrNuf/+ and CasrNuf/Nuf mice were significantly hypocalcemic compared with respective Casr+/+ mice. Treatment with 90-mg/kg
ronacaleret significantly increased plasma calcium concentrations in Casr+/+, CasrNuf/+, and CasrNuf/Nuf mice compared with respective mice treated
with the drug vehicle only. Ronacaleret treatment normalized the plasma calcium concentrations of CasrNuf/+ mice. However, the plasma calcium
concentrations of treated CasrNuf/Nuf mice remained significantly reduced compared with untreated Casr+/+ mice. Mean 6 standard error of the
mean values are indicated by solid bars. *P , 0.05, **P , 0.01, ***P , 0.001. NS, nonsignificant.
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treated with the drug vehicle alone (Figs. 3 and 4).
Moreover, sex differences were noted, as ronacaleret
normalized plasma glucose concentrations at 30 minutes
in male CasrNuf/+mice but only at 60 minutes in female
CasrNuf/+mice (Figs. 3 and 4). Ronacaleret treatment had
no effect on the plasma insulin concentrations of male
and female Casr+/+ mice (Figs. 3 and 4) but significantly
increased the plasma insulin concentrations of male and
femaleCasrNuf/+mice compared with untreatedCasrNuf/+
mice (Figs. 3 and 4). Ronacaleret treatment did not alter
plasma insulin concentrations in male and female
CasrNuf/Nuf mice (Figs. 3 and 4) and had no significant
effect on the plasma glucagon concentrations of male and
femaleCasr+/+,CasrNuf/+, orCasrNuf/Nufmice (Figs. 3 and
4). No significant differences were noted between the
biochemical responses of ronacaleret-treated male and
female mice (Supplemental Fig. 3). To evaluate the
mechanisms underlying these alterations of glucose tol-
erance and plasma insulin and glucagon concentrations
in Nuf mice, further ex vivo and electrophysiological
Figure 3. Effect of ronacaleret on the plasma glucose, insulin, and glucagon concentrations of male mice during IPGTT. Ronacaleret
administration had no effect on the plasma glucose concentrations of (a) Casr+/+ mice (black dashed line) but significantly lowered plasma
glucose in (b) CasrNuf/+ (blue dashed line) and (c) CasrNuf/Nuf mice (red dashed line) compared with respective control mice treated with the drug
vehicle only (represented by solid lines), so that the glucose concentrations were not significantly different from Casr+/+ mice. Ronacaleret had no
effect on the plasma insulin concentrations of (d) Casr+/+ mice but significantly increased plasma insulin in (e) CasrNuf/+ mice compared with
controls, so that the insulin concentrations were not significantly different from Casr+/+ mice. Ronacaleret treatment did not alter plasma insulin
concentrations in (f) CasrNuf/Nuf mice. Ronacaleret had no significant effect on the plasma glucagon concentrations of (g) Casr+/+ mice, (h) CasrNuf/+ mice,
or (i) CasrNuf/Nuf mice compared with respective control mice. Results are expressed as mean 6 standard error of the mean. *P , 0.05, **P , 0.01
compared with control mice.
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studies were undertaken. As no significant differences
had been observed for the glucose, insulin, and glucagon
responses of male and female mice, the ex vivo data were
combined for males and females.
Pancreatic islet size and proliferation
We assessed for alterations in islet morphology by
undertaking histological analysis of whole pancreases
from adult Casr+/+, CasrNuf/+, and CasrNuf/Nuf mice. This
revealed that the overall architecture of CasrNuf/+ and
CasrNuf/Nuf islets was similar to that in Casr+/+ mice
[Fig. 5(a)]. However, islet area, which was normalized to
body weight, was reduced by .40% in CasrNuf/+ and
CasrNuf/Nuf mice [Fig. 5(b)], and this was associated with
significant decreases in islet numbers and mean islet size
[Fig. 5(c) and 5(d)]. To assess whether the reduced islet
area may also be associated with alterations in the
numbers of b-cells or a-cells, whole pancreas sections
were immunostained for insulin and glucagon [Fig. 5(e)].
Individual islets from CasrNuf/Nuf mice had 5% to 10%
Figure 4. Effect of ronacaleret on the plasma glucose, insulin, and glucagon concentrations of female mice during IPGTT. Ronacaleret
administration had no effect on the plasma glucose concentrations of (a) Casr+/+ mice (black dashed line) but significantly lowered plasma
glucose in (b) CasrNuf/+ (blue dashed line) and (c) CasrNuf/Nuf mice (red dashed line) compared with respective control mice treated with the drug
vehicle only (represented by solid lines), so that the glucose concentrations were not significantly different from Casr+/+ mice. Ronacaleret had no
effect on the plasma insulin concentrations of (d) Casr+/+ mice but significantly increased plasma insulin in (e) CasrNuf/+ mice compared with
controls, so that the insulin concentrations were not significantly different from Casr+/+ mice. Ronacaleret treatment did not alter plasma insulin
concentrations in (f) CasrNuf/Nuf mice. Ronacaleret had no significant effect on the plasma glucagon concentrations of (g) Casr+/+ mice, (h) CasrNuf/+
mice, or (i) CasrNuf/Nuf mice compared with respective control mice. Results are expressed as mean 6 standard error of the mean. *P , 0.05,
**P , 0.01, ***P , 0.001 compared with control mice.
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fewer b-cells (P , 0.05) and approximately 20% more
a-cells than Casr+/+ islets (P , 0.05) [Fig. 5(f) and 5(g)].
To investigate whether the reduction in b-cells and in-
crease in a-cells were caused by alterations in cellular
proliferation, whole pancreas sections were immuno-
stained with the proliferation marker Ki-67. [Fig. 5(h)].
The percentage of proliferating insulin-positive b-cells in
CasrNuf/Nuf mice was found to be significantly decreased
(P , 0.05), whereas the percentage of proliferating
insulin-negative cells (which are predominantly a-cells)
was significantly increased when compared with re-
spective Casr+/+ islets [Fig. 5(i) and 5(j)]. qRT-PCR
analysis utilizing RNA from isolated Casr+/+ and
CasrNuf/Nuf islets revealed that these changes in b-cell and
a-cell proliferation were not associated with significant
alterations in the expression of genes regulating islet mass
such as Foxo1, Foxm1,Ngn3, andTcf7l2 (31–34), which
promote b-cell proliferation, or in the expression of genes
such as Arx and Irx2 (35), which influence a-cell pro-
liferation (Supplemental Fig. 4).
Insulin and glucagon secretion from isolated islets
To determine whether Nuf mice have alterations in
pancreatic islet insulin secretion, size-matched islets were
Figure 5. Histological analysis of Nuf mice pancreatic islets. (a) Representative H&E-stained pancreatic sections from Casr+/+, CasrNuf/+, and
CasrNuf/Nuf mice. Bars indicate 200 mm. (b) Islet area and (c) number are significantly reduced in CasrNuf/+ and CasrNuf/Nuf mice compared with
Casr+/+ mice. (d) Islet size is significantly reduced in CasrNuf/Nuf mice compared with Casr+/+ mice. (e) Representative pancreatic islets from Casr+/+,
CasrNuf/+, and CasrNuf/Nuf mice immunostained for glucagon (red), insulin (white), and DAPI (blue). Bars indicate 50 mm. (f) CasrNuf/Nuf mice have
significantly reduced b-cell numbers and (g) significantly increased a-cell numbers compared with Casr+/+ mice. (h) b-cell proliferation in
representative islets from Casr+/+, CasrNuf/+, and CasrNuf/Nuf mice immunostained for insulin (white), DAPI (blue), and KI-67 (red). KI-67–positive
cells are also indicated by yellow arrows. Bars indicate 50 mm. (i) CasrNuf/Nuf mice have significantly reduced proliferation of b-cells and (j)
significantly increased proliferation of a-cells compared with respective Casr+/+ mice. Results are expressed as mean 6 standard error of the
mean. *P , 0.05, **P , 0.01 compared with Casr+/+ mice.
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isolated from Casr+/+ and CasrNuf/Nuf mice and exposed
to low (1 mM), physiological (6 mM), or high (20 mM)
glucose concentrations in the presence of 1.6 mM [Ca2+]o,
which represents a physiological [Ca2+]o (36). The insulin
content of isolated CasrNuf/Nuf islets was not significantly
different from isolated Casr+/+ islets
[Fig. 6(a)]. Measurement of insulin in
the supernatant of islets following
glucose stimulation did not reveal any
impairment in the insulin secretory re-
sponses of isolated CasrNuf/Nuf islets
compared with Casr+/+ islets [Fig. 6(b)].
We also investigated whether glucagon
secretion may be altered in Nuf mouse
islets. Compared with Casr+/+ islets,
there was a .30% increase in the glu-
cagon content [Fig. 6(c)] of CasrNuf/Nuf
islets. Increasing glucose from1 to6mM
resulted in a 60% reduction of glucagon
secretion from isolated Casr+/+ islets
[Fig. 6(d)]. In contrast, islets from
CasrNuf/Nuf mice exhibited a lack of
glucose-induced suppression of gluca-
gon release [Fig. 6(d)], which is consis-
tent with that observed in islets from
type 2 diabetic patients (37). To in-
vestigate whether the reduced plasma
insulin concentrations of Nuf mice may
have been a consequence of their hy-
pocalcemia, insulin secretion from iso-
lated islets was measured following
exposure to 0.8 mM [Ca2+]o, which is
similar to the plasma calcium concen-
trations observed in CasrNuf/Nuf mice
(15, 16). Altering the [Ca2+]o had no
effect on insulin secretion in the presence
of low (1 mM) glucose concentrations
[Fig. 6(e)]. However, exposure to low
(0.8 mM) Ca2+o impaired insulin se-
cretion from Casr+/+ and CasrNuf/Nuf
islets in the presence of high (20 mM)
glucose concentrations [Fig. 6(e)]. Ex-
posure to low (0.8 mM) Ca2+o increased
glucagon secretion from Casr+/+ islets at
20 mM glucose but had no effect on
glucagon secretion from CasrNuf/Nuf is-
lets [Fig. 6(f)].
Electrophysiological studies of
isolated islets
We investigated alterations in b-cell
electrical activity by recording the
membrane potential of b-cells within
intact Casr+/+ and CasrNuf/Nuf islets on treatment with
varying (1, 12, or 20 mM) concentrations of glucose, or
tolbutamide, which is a KATP channel blocker (26). The
electrophysiological experiments were undertaken at
1.5 mM [Ca2+]o, as described (25), and the effect of
Figure 6. Insulin and glucagon secretion from isolated Nuf mice pancreatic islets. (a) The
total insulin content of CasrNuf/Nuf islets was not altered compared with Casr+/+ islets. (b) Casr+/+
and CasrNuf/Nuf islets were incubated in 1.6 mM [Ca2+]o and exposed to varying glucose
concentrations (1, 6, or 20 mM). Casr+/+ and CasrNuf/Nuf islets showed significantly increased
insulin secretion following stimulation with 20 mM glucose. No significant differences in the
maximal insulin secretory responses were observed between Casr+/+ and CasrNuf/Nuf islets. (c)
The total glucagon content of CasrNuf/Nuf islets was significantly increased compared with
Casr+/+ islets. (d) Casr+/+ and CasrNuf/Nuf islets were incubated in 1.6 mM [Ca2+]o and exposed
to 1 and 6 mM glucose concentrations. Casr+/+ islets showed a significant reduction in
glucagon secretion following stimulation with 6 mM glucose. In contrast, glucagon secretion
from CasrNuf/Nuf islets failed to suppress following glucose stimulation, and CasrNuf/Nuf islets
had significantly increased glucagon secretion compared with Casr+/+ islets at 6 mM glucose.
(e) The effect of Ca2+o on insulin secretion was assessed by incubating Casr
+/+ and CasrNuf/Nuf
islets with varying Ca2+o concentrations (0.8 or 1.6 mM) and exposing them to low (1 mM)
or high (20 mM) glucose. Exposure to low (0.8 mM) Ca2+o suppressed insulin secretion from
Casr+/+ and CasrNuf/Nuf islets at 20 mM glucose. (f) Exposure to low (0.8 mM) Ca2+o increased
glucagon secretion from Casr+/+ islets at 20 mM glucose but had no effect on glucagon
secretion from CasrNuf/Nuf islets. Islet insulin and glucagon in panels (a–d) were measured by
radioimmunoassay and by duplex rat/mouse ELISA (Meso Scale Discovery) in panels (e) and
(f). The sample size (N) represents batches of size-matched islets, which were pooled from
three to six Casr+/+ mice and six CasrNuf/Nuf mice. Mean 6 standard error of the mean values
for the respective groups are indicated by solid bars. *P , 0.05, **P , 0.01, ***P , 0.001.
NS, nonsignificant.
doi: 10.1210/en.2017-00111 https://academic.oup.com/endo 2495
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/article-abstract/158/8/2486/3860207 by U
niversity of U
lster user on 05 February 2020
lowering the [Ca2+]o on b-cell electrical activity was
evaluated at 0.75 mM [Ca2+]o, which is in keeping with
the plasma calcium concentrations of CasrNuf/Nuf
mice (15, 16). Analysis of membrane potentials showed
b-cells from Casr+/+mice (i.e., WTs) to be hyperpolarized
(–76 6 2 mV) and electrically silent at 1 mM glucose
concentrations [Fig. 7(a)]. In contrast, CasrNuf/Nuf b-cells
were significantly depolarized (–636 5 mV; P, 0.01) at
1 mM glucose, and .40% of cells (four of nine) were
electrically active with low-frequency action potential
firing [Fig. 7(a)]. The depolarization and hyperactivity of
CasrNuf/Nuf b-cells were rectified by lowering [Ca2+]o
from 1.5 to 0.75 mM [Fig. 7(b) and 7(c)]. At stimulatory
glucose concentrations (12 or 20 mM) or following ap-
plication of tolbutamide, both Casr+/+ and CasrNuf/Nuf
b-cells were depolarized and firing action potentials
[Fig. 7(a) and 7(b)], and the level of the depolarization
was not altered in CasrNuf/Nuf b-cells [Fig. 7(c)]. How-
ever, the peak of action potential evoked by 20 mM
glucose in CasrNuf/Nuf b-cells was significantly reduced
compared with Casr+/+ b-cells [Fig. 7(d)]. The antipeak
potential and firing frequency were not affected by the
expression of the Casr mutation or variation in [Ca2+]o
[Fig. 7(e) and 7(f)]. Based on the observation that
CasrNuf/Nuf b-cells were significantly depolarized at
1 mM glucose, we postulated that the CaSR may in-
fluence the KATP channel, which plays a central role in
regulating the membrane potential of b-cells (1). We
therefore measured resting conductance, which pre-
dominantly reflects KATP channel activity, ofCasr
+/+ and
Figure 7. Effect of glucose stimulation on the electrical activity of Nuf mice b-cells. (a) Representative membrane potential recording of b-cells
from intact Casr+/+ and CasrNuf/Nuf islets, which had been incubated in 1.5 mM [Ca2+]o and following stimulation with 1 mM (1G), 12 mM (12G),
and 20 mM (20G) glucose concentrations or with tolbutamide (Tolb). (b) Representative membrane potential recording of b-cells from intact
Casr+/+ and CasrNuf/Nuf islets in the presence of 0.75 mM Ca2+o concentrations and following stimulation with 1, 12, or 20 mM glucose
concentrations or with tolbutamide. (c) Basal membrane potential, (d) action potential peak, (e) antipeak potential, and (f) frequency of
action potential firing from b-cells was assessed in intact Casr+/+ (white bars) and CasrNuf/Nuf islets (black bars) in the presence of 1.5 or
0.75 mM Ca2+o concentrations and following stimulation with glucose or tolbutamide. The sample size (N) represents individual b-cell
recordings obtained from intact islets of six Casr+/+ mice and four CasrNuf/Nuf mice. Results are expressed as mean 6 standard error of the
mean. *P , 0.05, **P , 0.01 compared with Casr+/+ mice at respective glucose and Ca2+o concentrations.
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CasrNuf/Nuf b-cells in the presence of 1, 12, or 20 mM
glucose, or with tolbutamide. These studies showed
b-cell resting conductance to be comparable between
genotypes [Fig. 8(a) and 8(b)]. However, the holding
current measured at –70 mV in CasrNuf/Nuf b-cells when
KATP channel activity was suppressed by 20 mMglucose
or tolbutamide was significantly greater than in Casr+/+
b-cells [Fig. 8(c) and 8(d)], and its contribution likely
accounts for the more depolarized membrane potential
and action potential firing inCasrNuf/Nuf b-cells exposed
to 1 mM glucose [Fig. 7(a)].
To determine whether Nuf mice may also have al-
terations in a-cell electrical activity, membrane potentials
were recorded in intact islet a-cells, as described (26). In
agreement with previous reports (37), Casr+/+ a-cells
were shown to be electrically active at 1 mM glucose
[Fig. 9(a)]. The addition of 6 mM glucose led to a small
but statistically significant (P, 0.01) depolarization and
reduction in action potential peak [Fig. 9(a)]. CasrNuf/Nuf
a-cells were also electrically active at 1 mM glucose
[Fig. 9(b)] but did not depolarize when glucose was in-
creased to 6 mM [Fig. 9(b) and 9(c)], and there was no
change in the action potential peak [Fig. 9(b) and 9(d)].
The addition of tolbutamide led to membrane de-
polarization in both Casr+/+ and CasrNuf/Nuf a-cells [Fig.
9(a) and 9(b)], but the magnitude of the depolarizing
effect was reduced in CasrNuf/Nuf a-cells [Fig. 9(c)].
Tolbutamide also decreased the action potential peak of
Casr+/+ a-cells but had no significant effect on the action
potential peak of CasrNuf/Nuf a-cells [Fig. 9(a), 9(b), and
9(d)]. There were no significant differences in the action
potential frequency between Casr+/+ and CasrNuf/Nuf
a-cells, and this was not affected by varying glucose or the
addition of tolbutamide [Fig. 9(e)].
Discussion
Our studies have shown an in vivo role for the CaSR in
glucose homeostasis and in the regulation of pancreatic
islet mass and islet hormone secretion. Thus, Nuf mice
with a gain-of-function CaSR mutation exhibited im-
paired glucose tolerance, which was associated with re-
duced pancreatic islet mass and hypoinsulinemia as well
as a lack of glucose-mediated suppression of glucagon
secretion. Moreover, these findings indicate that ADH-
causing mutations of the CaSR, which lead to a gain-of-
function (14), may perturb systemic glucose homeostasis,
and this contrasts with FHH-causing loss-of-function
CaSR mutations, which have been shown to not influ-
ence glucose tolerance or insulin secretion (13). Fur-
thermore, these findings suggest that a common coding
region CaSR variant (Ala986Ser), which was reported in
association with raised plasma glucose concentrations
in a patient-based study (12), may have altered CaSR
function in tissues involved in systemic glucose regula-
tion. However, impaired glucose tolerance or diabetes
has not been reported in ADH patients to date, and
detailed investigations of glucose homeostasis in humans
are warranted.
Although our studies showed CaSR activation to in-
fluence plasma glucose concentrations, we did not observe
any effect of extracellular glucose on the acute signaling
responses of WT or mutant Nuf CaSRs in vitro. Our
findings are consistent with results obtained by other
groups (Arthur Conigrave and Donald Ward, personal
communication) but contrast with a recent study, which
showed that raising the glucose concentration from 3 to
5 mM increased the Ca2+i responses of stably expressing
HEK293-CaSR cells in the presence of Ca2+o (30). This
recent study, which showed glucose to act as a CaSR al-
losteric activator, measured Ca2+i responses in single cells
using the fluo-8 calcium binding dye (30), whereas our
study measured Ca2+i responses in populations of
HEK293-CaSR cells using the fluo-4 calcium binding dye,
and these methodological differences may be contributors
to the contrasting observations of these two studies.
The CaSR is a therapeutic target for calcitropic dis-
eases (14, 38), and our studies involving the adminis-
tration of ronacaleret, which is a calcilytic compound, to
Nuf mice showed that pharmacological modulation of
the CaSR may also alter plasma glucose concentrations.
Ronacaleret treatment rectified the hypocalcemia of
heterozygous-affected (CasrNuf/+) mice, and this was as-
sociated with an increase in plasma insulin concentra-
tions. Thus, these findings suggest that ronacaleret
rectified the impaired glucose tolerance and hypo-
insulinemia ofCasrNuf/+mice by modulating their plasma
calcium concentrations, and this is in keeping with our
analysis of isolated Nuf mice islets, which demonstrated
that Ca2+o is required for insulin release, and is also
supported by a study showing that patients with chronic
hypocalcemia have reduced glucose-stimulated insulin
secretion (39). However, ronacaleret treatment also im-
proved the glucose tolerance of homozygous-affected
(CasrNuf/Nuf) mice without fully normalizing their
plasma calcium concentrations or altering plasma insulin
or glucagon concentrations. Thus, these studies involving
CasrNuf/Nuf mice suggest that ronacaleret likely had ad-
ditional effects on the glucose tolerance of Nuf mice,
independently of altering plasma concentrations of cal-
cium, insulin, and glucagon. The CaSR is expressed in
peripheral tissues such as skeletal muscle and adipose
tissue (40, 41), and it remains to be established whether
ronacaleret treatment may potentially have sensitized
these tissues to the actions of insulin, thereby improving
glucose tolerance.
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Figure 8. KATP channel conductance of Nuf mice b-cells. (a) Representative recording of b-cell KATP channel conductance from intact Casr
+/+
and CasrNuf/Nuf islets after islets had been incubated in 1.5 mM [Ca2+]o and following stimulation with 1 mM (1G), 12 mM (12G), and 20 mM
(20G) glucose concentrations or with tolbutamide (Tolb). (b) Analysis of KATP channel conductance from b-cells within intact Casr
+/+ (white bars)
and CasrNuf/Nuf islets (black bars) following stimulation with glucose or tolbutamide. (c) Representative traces of b-cell background current
measurement following glucose stimulation or treatment with tolbutamide. (d) Analysis of holding current from b-cells within intact Casr+/+
(white bars) and CasrNuf/Nuf islets (black bars) following stimulation with glucose or tolbutamide. The sample size (N) represents individual b-cell
recordings obtained from intact islets of five Casr+/+ mice and five CasrNuf/Nuf mice. Results are expressed as mean 6 standard error of the mean.
*P , 0.05, **P , 0.01 compared with Casr+/+ mice at respective glucose and tolbutamide concentrations.
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Histological analysis revealed Nuf mice to have a
significant reduction inmean islet area, and these findings
may have contributed to their reduced plasma insulin
concentrations and impaired glucose tolerance. Indeed, a
decrease in pancreatic b-cell mass is considered to be
important in the pathogenesis of type 2 diabetes, as
highlighted by a study of a mouse model with restricted
b-cell expansion, which showed that a 30% reduction in
b-cell mass is sufficient to result in impaired glucose
tolerance (42). Our histological analyses also revealed
individual CasrNuf/Nuf islets to have a significant re-
duction in the proportion of b-cells comparedwithCasr+/+
islets. Thus, these findings indicate that the CaSR may
influence pancreatic islet size and the cellular composition
of individual islets and suggest a role for this GPCR in the
development and/or maintenance of b-cell mass. In
support of this, mouse model studies of the a-2A
adrenergic receptor, which is highly expressed in b-cells,
have shown GPCR signaling to play a critical role in
modulating pancreatic islet mass by inhibiting b-cell
proliferation during the perinatal period (42). In keeping
with this observation, CaSR activation was also associ-
ated with significantly reduced b-cell proliferation in
adult CasrNuf/Nuf islets, which may have contributed to
the reduced size of Nuf mouse islets. However, b-cell
proliferationwasmeasured using the Ki67marker, which
shows proliferation over a limited timeframe, and long-
term continuous labeling with the thymidine analog
5-bromo-2-deoxyuridine is required to provide a more
accurate assessment of proliferation (43). Moreover,
genes reported to be involved in the regulation of islet cell
proliferation did not show altered expression in
CasrNuf/Nuf islets. Thus, it is possible that the gain-of-
function CaSRmutation harbored byNufmice may have
Figure 9. Effect of glucose stimulation on the electrical activity of Nuf mice a-cells. Representative membrane potential recording of a-cells from
(a) intact Casr+/+ and (b) CasrNuf/Nuf islets, which had been incubated in 1.5 mM [Ca2+]o and following stimulation with 1 mM (1G) and 6 mM
(6G) glucose concentrations or with tolbutamide (Tolb). (c) Antipeak potential, (d) action potential peak, and (e) frequency of action potential
firing was assessed in a-cells within intact Casr+/+ (white bars) and CasrNuf/Nuf islets (black bars) following stimulation with glucose or tolbutamide.
The sample size (N) represents individual a-cell recordings obtained from intact islets of five Casr+/+ mice and seven CasrNuf/Nuf mice. Results are
expressed as mean 6 standard error of the mean. *P , 0.05, **P , 0.01 compared with respective a-cells at 1 mM glucose.
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exerted a greater influence on islet size during the peri-
natal and early postnatal periods, when the b-cell pop-
ulation is undergoing a rapid expansion, and at this key
developmental stage, alterations in cellular proliferation
can have a substantial impact on adult b-cell mass and
insulin secretory capacity (42). Furthermore, the CaSR
may have influenced b-cell apoptosis, which has been
shown to contribute to the reduced islet mass in humans
with type 2 diabetes (44).
Isolated Nuf mouse islets were shown to have alter-
ations in b-cell electrical activity, and CasrNuf/Nuf b-cells
were significantly depolarized and electrically active at
low glucose concentrations. These findings suggest that
the CaSR may influence the basal electrical activity of the
b-cell, most likely by increasing background conductance
(Fig. 8). In support of this, lowering the concentration of
Ca2+o, which represents the major physiological ligand
of the CaSR (14), rectified the increased basal activity of
CasrNuf/Nuf b-cells. Although the KATP channel plays an
essential role in regulating the b-cell resting membrane
potential (45), KATP channel conductance was not altered
in CasrNuf/Nuf b-cells, and the higher background con-
ductancewas resistant to the effects of tolbutamide. Thus,
the basal hyperactivity of CasrNuf/Nuf b-cells may have
been mediated by a KATP channel–independent mecha-
nism. A previous study has demonstrated that the tran-
sient receptor potential (TRP) M4 and TRPM5 ion
channels regulate b-cell membrane potential, and acti-
vation of these channels leads to increased b-cell electrical
activity (25). As TRPM4 and TRPM5 channels have been
shown to be activated by Gq/11-mediated phosphoino-
sitide signaling (25), it is possible that CaSR activation
induced depolarization and hyperactivity of b-cells by
enhancing the opening of these channels. However, due
to a lack of selective channel blockers, it remains to be
established whether CaSR may act via TRPM4 and
TRPM5 in b-cells. Interestingly, the increased electrical
activity of CasrNuf/Nuf b-cells at 1 mM glucose was not
associated with an increase in basal insulin secretion. The
release of insulin has been shown to be mediated by a
combination of triggering effects (mediated by KATP
channel closure and initiation of action potential firing)
and late amplifying effects (exerted at the level of insulin
granule exocytosis) (1). Thus, although CasrNuf/Nuf
b-cells generated action potentials at low glucose, this
may not necessarily have stimulated insulin secretion.
Moreover, the CaSR did not influence the overall re-
sponses of b-cells to stimulatory glucose concentrations;
however, a reduced spike height of the glucose-induced
action potentials inCasrNuf/Nuf b-cells was observed. The
generation of action potentials in b-cells is mediated by
Ca2+ influx through the L-type voltage-dependent Ca2+
channel (VDCC) (46), and our observation of altered
action potential height provides support for an in-
teraction between the CaSR and L-type VDCC, as has
been previously reported (47).
A key finding in this study was the presence of dys-
regulated glucagon secretion and altered a-cell function
in CasrNuf/Nuf mice. Glucagon plays a central role in
systemic glucose homeostasis by stimulating hepatic
glucose production, and oversecretion of glucagon con-
tributes to the hyperglycemia in type 2 diabetes (48). The
release of glucagon from a-cells is physiologically
inhibited by elevations in glucose concentrations (26, 48).
However, high glucose concentrations failed to sup-
press glucagon secretion from CasrNuf/Nuf islets. We in-
vestigated whether alterations in the electrical activity of
CasrNuf/Nuf a-cells may have impaired the suppression of
glucagon secretion following exposure to high glucose. In
WT a-cells, glucose regulates glucagon secretion via clo-
sure of the KATP channel, and the resulting membrane
depolarization leads to reduced activation of P/Q-type
VDCCs that mediate the Ca2+ entry responsible for
hypoglycemia-induced glucagon secretion (26, 37, 48).
However, in CasrNuf/Nuf a-cells, glucose did not induce
membrane depolarization, and tolbutamide only caused a
modest depolarization (approximately 2 mV), whereas
this KATP channel blocker increased membrane potential
by approximately 10 mV in Casr+/+ a-cells (Fig. 9). To-
gether, these data suggest that CaSR activation may have
attenuated a-cell basal KATP channel activity, which im-
paired the membrane depolarizing effect of glucose and
tolbutamide. Furthermore, CasrNuf/Nuf mice exhibited an
increase in a-cell numbers within individual islets, en-
hanceda-cell proliferation rates, and significantly elevated
islet glucagon content. These findings highlight a potential
and unique role for the CaSR in promoting a-cell neo-
genesis, but it is also possible that the hypoinsulinemia of
Nuf mice may have led to an expansion of a-cells, as has
previously been reported in mice with streptozotocin-
induced insulin deficiency (49).
In conclusion, we have demonstrated that Nuf mice
with a germline gain-of-function CaSR mutation have
impaired glucose tolerance, which can be ameliorated by
calcilytic treatment. Moreover, our findings reveal a role
for the CaSR in the regulation of pancreatic islet mass and
a- and b-cell function.
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